Spectrum of infection and outcomes in individuals with Candida auris infection in Qatar.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2024
Historique:
received: 23 12 2023
accepted: 05 04 2024
medline: 23 5 2024
pubmed: 23 5 2024
entrez: 23 5 2024
Statut: epublish

Résumé

We investigated the spectrum of infection and risk factors for invasive fungal disease due to Candida auris (CA) in Qatar. We performed structured chart reviews on individuals with any positive CA culture between May 2019 and December 2022 at three tertiary care hospitals in Qatar. Invasive CA disease (ICAD) was defined as a positive sterile site culture, or any positive culture for CA with appropriate antifungal prescription. Main outcomes included proportion of individuals who developed ICAD among those with positive cultures, and 30-day/in-hospital mortality. Among 331 eligible individuals, median age was 56 years, 83.1% were male, 70.7% were non-Qataris, and 37.5% had ≥ 3 comorbidities at baseline. Overall, 86.4% were deemed to have colonization and 13.6% developed ICAD. Those with ICAD were more likely to have invasive central venous or urinary catheterization and mechanical ventilation. Individuals with ICAD had longer prior ICU stay (16 vs 26 days, P = 0.002), and longer hospital length of stay (63 vs. 43 days; P = 0.003), and higher 30-day mortality (38% vs. 14%; P<0.001). In multivariable regression analysis, only mechanical ventilation was associated with a higher risk of ICAD (OR 3.33, 95% CI 1.09-10.17). Invasive Candida auris Disease is associated with longer hospital stay and higher mortality. Severely ill persons on mechanical ventilation should be especially monitored for development of ICAD.

Sections du résumé

BACKGROUND BACKGROUND
We investigated the spectrum of infection and risk factors for invasive fungal disease due to Candida auris (CA) in Qatar.
METHODS METHODS
We performed structured chart reviews on individuals with any positive CA culture between May 2019 and December 2022 at three tertiary care hospitals in Qatar. Invasive CA disease (ICAD) was defined as a positive sterile site culture, or any positive culture for CA with appropriate antifungal prescription. Main outcomes included proportion of individuals who developed ICAD among those with positive cultures, and 30-day/in-hospital mortality.
RESULTS RESULTS
Among 331 eligible individuals, median age was 56 years, 83.1% were male, 70.7% were non-Qataris, and 37.5% had ≥ 3 comorbidities at baseline. Overall, 86.4% were deemed to have colonization and 13.6% developed ICAD. Those with ICAD were more likely to have invasive central venous or urinary catheterization and mechanical ventilation. Individuals with ICAD had longer prior ICU stay (16 vs 26 days, P = 0.002), and longer hospital length of stay (63 vs. 43 days; P = 0.003), and higher 30-day mortality (38% vs. 14%; P<0.001). In multivariable regression analysis, only mechanical ventilation was associated with a higher risk of ICAD (OR 3.33, 95% CI 1.09-10.17).
CONCLUSION CONCLUSIONS
Invasive Candida auris Disease is associated with longer hospital stay and higher mortality. Severely ill persons on mechanical ventilation should be especially monitored for development of ICAD.

Identifiants

pubmed: 38781160
doi: 10.1371/journal.pone.0302629
pii: PONE-D-23-43429
doi:

Substances chimiques

Antifungal Agents 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0302629

Informations de copyright

Copyright: © 2024 Al Ajmi et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Déclaration de conflit d'intérêts

Dr. Butt has received investigator-initiated grant funding from Gilead Sciences and Merck and Company (to the institution, Veterans Health Foundation of Pittsburgh) which are unrelated to the work presented here. This does not alter our adherence to PLOS ONE policies on sharing data and materials.

Auteurs

Jameela A Al Ajmi (JA)

Corporate Quality and Patient Safety Department, Hamad Medical Corporation, Doha, Qatar.

Aimon B Malik (A)

Corporate Quality and Patient Safety Department, Hamad Medical Corporation, Doha, Qatar.

Hanaa Nafady-Hego (H)

Microbiology and Immunology, Faculty of Medicine, Assiut University, Assiut, Egypt.

Fathima Hanana (F)

Corporate Quality and Patient Safety Department, Hamad Medical Corporation, Doha, Qatar.

Joji Abraham (J)

Corporate Quality and Patient Safety Department, Hamad Medical Corporation, Doha, Qatar.

Humberto G Garcell (H)

Infection Prevention and Control Department, The Cuban Hospital, Dukhan, Qatar.

Ghada Hudaib (G)

Corporate Quality and Patient Safety Department, Hamad Medical Corporation, Doha, Qatar.

Walid Al-Wali (W)

Department of Microbiology and Laboratory Medicine, Hamad Medical Corporation, Doha, Qatar.

Faiha Eltayeb (F)

Department of Microbiology and Laboratory Medicine, Hamad Medical Corporation, Doha, Qatar.

Sherin Shams (S)

Corporate Quality and Patient Safety Department, Hamad Medical Corporation, Doha, Qatar.

Anil G Thomas (A)

Corporate Quality and Patient Safety Department, Hamad Medical Corporation, Doha, Qatar.

Samah Saleem (S)

Corporate Quality and Patient Safety Department, Hamad Medical Corporation, Doha, Qatar.

Abdul-Badi Abou-Samra (AB)

Corporate Quality and Patient Safety Department, Hamad Medical Corporation, Doha, Qatar.

Adeel A Butt (AA)

Corporate Quality and Patient Safety Department, Hamad Medical Corporation, Doha, Qatar.
Department of Medicine and Population Health Sciences, Weill Cornell Medicine, New York, NY, United States of America.
Department of Medicine and Population Health Sciences, Weill Cornell Medicine, Education City, Qatar.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH